AIDOT (CEO Jung Jae-hoon) announced on April 19 that it was selected as a “High-Growth Company” in the 2023 SW High-Growth Club, hosted by the National IT Industry Promotion Agency (NIPA) and overseen by the Ministry of Science and ICT (MSIT). The company said it was recognized for the innovative business model and global scalability of its AI-based remote cervical cancer screening system, Cerviray AI, as well as five additional AI screening systems.

The SW High-Growth Club is a government support program designed to promote the growth of Korea’s software industry and job creation by identifying “High-Growth” and “Preliminary High-Growth” companies with strong global expansion potential and providing tailored support. The program is overseen by MSIT and hosted by NIPA.

CEO Jung Jae-hoon stated, “Through this selection as a high-growth company, we will receive support through various programs such as network-building and global mentoring. We will use this as an important stepping stone to expand into many more countries, building on our progress in 15 countries including Indonesia and Mongolia.”

AIDOT added that it is a medical ICT company that previously received the Minister’s Award in the SW High-Growth Club’s “Preliminary High-Growth” program (2020). The company said its model—combining healthcare and AI to overcome barriers such as cost, facilities, and workforce limitations and to improve access to medical infrastructure—along with its global expansion momentum, contributed to its selection as a high-growth company.

The company also noted that since its founding it has been recognized through selection for multiple government-supported projects, and that it has expanded into global markets—particularly Southeast Asia—through its AI-based cervical cancer screening/reading system, Cerviray AI. In addition, AIDOT highlighted its pipeline including real-time AI solutions for upper and lower GI endoscopy (GIGA dot AI and COLON dot AI) and a microbiome-based AI diagnostic system for alcoholic chronic liver disease (BIO dot AI), stating that it is accelerating preparations to commercialize its next products alongside Cerviray AI.

Published: April 19, 2023 / Korea Economic TV / Reporter Park Jun-sik